Attention deficit hyperactivity disorder (ADHD) - Clinical trials 

  • Clinical trials

Clinical trials for Attention deficit hyperactivity disorder (ADHD)

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Attention deficit hyperactivity disorder (ADHD). For all clinical trials, go to clinical trials search

This list shows clinical trials for Attention deficit hyperactivity disorder (ADHD)

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Attention deficit hyperactivity disorder (ADHD)
Title Recruitment status Location
Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) Recruiting United Kingdom
Female Experiences and Brain Activity Recruiting United Kingdom
Cognitive-Behavioural Therapy (CBT) for Adult Attention Deficit Hyperactivity Disorder (ADHD) Recruiting United Kingdom
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) Recruiting United Kingdom
Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate Recruiting United Kingdom
Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects Recruiting United Kingdom
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD) Recruiting United Kingdom
Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 Not recruiting United Kingdom
Investigating the neural basis of inhibition, set-shifting and monitoring in obsessive-compulsive disorder (OCD), attention-deficit hyperactivity disorder (ADHD) and healthy volunteers Not recruiting United Kingdom
Estudio en Fase III, aleatorizado, doble ciego, multicéntrico, de grupos paralelos, controlado con placebo y con fármaco activo sobre la seguridad y eficacia de la optimización de dosis de Lisdexanfetamina Dimesilato (LDX) en niños y adolescentes de 6 a 17 años con Trastorno por Déficit de Atención con Hiperactividad (TDAH). A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD) Not Recruiting United Kingdom
  • Link to Directgov – public services all in one place
  • The Information Standard - Certified member